KCI Announces FDA Clearance of ABThera Open Abdomen Dressing

SAN ANTONIO--(Business Wire)--
Kinetic Concepts, Inc. (NYSE: KCI) announced today that it has received 510(k)
clearance from the U.S. Food and Drug Administration (FDA) to market its ABThera
Open Abdomen Dressing. Earlier this year, the FDA cleared the ABThera Open
Abdomen Negative Pressure Therapy Unit. Together, the ABThera Open Abdomen
Negative Pressure Therapy System will be indicated for temporary bridging of
abdominal wall openings where primary closure is not possible or repeat
abdominal entries are necessary. The intended use of the system is for open
abdominal wounds, with exposed viscera, including but not limited to abdominal
compartment syndrome.

This unique, proprietary system is designed to improve therapy in the management
of the complex open abdomen by actively removing fluids and infectious material,
and by reducing interstitial edema, thus assisting in primary fascial closure of
abdominal wall. The ABThera Open Abdomen Negative Pressure Therapy System
expands the offerings of KCI`s negative pressure technology platform into the
surgical and trauma operating theaters.

"We are pleased to receive clearance for this important therapy," said Catherine
M. Burzik, KCI`s President and CEO. "At KCI, we continue to leverage our
strengths and core technology competencies to provide high impact therapies and
address clinical unmet needs. Expansion and growth in the surgical arena is a
strategic goal for the company and we look forward to launching the ABThera Open
Abdomen Negative Pressure Therapy System this summer."

About KCI

Kinetic Concepts, Inc. is a leading global medical technology company devoted to
the discovery, development, manufacture and marketing of innovative,
high-technology therapies and products for the wound care, tissue regeneration
and therapeutic support system markets. Headquartered in San Antonio, Texas,
KCI's success spans more than three decades and can be traced to a history
deeply rooted in innovation and a passion for significantly improving the
healing - and the lives - of patients around the world.

KCI's three primary businesses include:

Advanced Wound Care - Includes KCI's proprietary Vacuum Assisted Closure, or
V.A.C. Therapy System, which has been clinically demonstrated to promote wound
healing through unique mechanisms of action while reducing the overall cost of
treating patients with complex wounds.

Regenerative Medicine - Represented by KCI's LifeCell business and includes
tissue-based products for use in reconstructive, orthopedic and urogynecologic
surgical procedures to repair soft tissue defects.

Therapeutic Support Systems - Includes specialty hospital beds, mattress
replacement systems and overlays designed to address pulmonary complications
associated with immobility, to reduce skin breakdown and assist caregivers in
the safe and dignified handling of patients of size.

The company employs 6,700 people and markets its products in more than 20
countries. For more information about KCI, and how its products are changing the
practice of medicine, visit www.KCI1.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding the expected
impact of the litigation ruling and the Company`s future plans. Forward-looking
statements may contain words such as believes, expects, anticipates, estimates,
projects, intends, should, seeks, future, continue, or the negative of such
terms, or other comparable terminology. Forward-looking statements are subject
to risks, uncertainties, assumptions and other factors that are difficult to
predict and that could cause actual results to vary materially from those
expressed in or indicated by them. Additional risks and factors are identified
in KCI's filings with the U.S. Securities Exchange Commission (the SEC),
including its Annual Report on Form 10-K for the fiscal year ending December 31,
2008 which is available on the SEC's Web site at http://www.sec.gov. KCI
undertakes no obligation to revise or update any forward-looking statement, or
to make any other forward-looking statements, whether as a result of new
information, future events or otherwise.

Kinetic Concepts, Inc., San Antonio
Investor Relations:
Adam Rodriguez, 210-255-6197
adam.rodriguez@kci1.com
or
Media Relations:
Jim Cravens, 210-255-6456
jim.cravens@kci1.com

Copyright Business Wire 2009